The limited extent of the anti-viral effects of EpMs, IFNα or their combination, suggests that genetic defects in JAK1/STAT1 signaling may play a prominent role in determining the susceptibility of a subset of prostate cancer cells to virotherapy, even under conditions of combined treatment with EpMs. The gene discussed is IFNA1; the disease is prostate carcinoma.